Evaluating Perioperative Outcomes: Dexmedetomidine vs Lignocaine in Laparoscopic Chlolecystectomy
Launched by SAHIWAL MEDICAL COLLEGE SAHIWAL · Dec 14, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two medications, dexmedetomidine and lignocaine, to see which one better helps manage pain and maintains stable heart function during and after laparoscopic cholecystectomy surgery, a common procedure to remove the gallbladder. The goal is to find out if one of these drugs can reduce the need for traditional pain medications, which can sometimes have unwanted side effects. The trial will take place at Sahiwal Teaching Hospital over the next year, and it will involve 140 patients who will be randomly assigned to receive either dexmedetomidine or lignocaine during their surgery.
Eligible participants are adults aged 20 to 70 who are scheduled to have laparoscopic cholecystectomy under general anesthesia, and who are generally in good health (classified as ASA I or II). However, individuals with certain health conditions, like severe heart disease or uncontrolled diabetes, or those who have had allergic reactions to these medications will not be included. Throughout the trial, researchers will monitor patients' heart rates and blood pressure, as well as their pain levels after surgery to evaluate how well each medication works. Participants can expect close observation and care during their hospital stay.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients of age 20-70 years
- • 2. Both gender
- • 3. Laparoscopic cholecystectomy under general Anaesthesia
- • 4. ASA I-II.
- Exclusion Criteria:
- • Emergency surgery
- • Patients with history of allergic reaction to trial drugs
- • Patients with cardiovascular disease, sickle cell disease, psychiatric disorder, peripheral vascular disease, and neurological diseases (on medical record)
- • Anemia
- • Patient on TCA or Beta blocker drugs.
- • Uncontrolled hypertension (P≥160/100 mmHg)
- • Uncontrolled diabetes mellitus
- • Obesity BMI \> 35
About Sahiwal Medical College Sahiwal
Sahiwal Medical College, located in Sahiwal, Pakistan, is a premier institution dedicated to advancing medical education and research. As a clinical trial sponsor, the college is committed to fostering innovative healthcare solutions through rigorous scientific investigation. The institution collaborates with a diverse network of researchers and healthcare professionals to conduct ethical and impactful clinical trials, aimed at improving patient outcomes and contributing to the global medical community. With a focus on quality and integrity, Sahiwal Medical College strives to enhance medical knowledge while adhering to the highest standards of clinical practice and regulatory compliance.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sahiwal, Punjab, Pakistan
Patients applied
Trial Officials
Adeel Riaz, MD
Study Director
Sahiwal Teaching Hospital, Sahiwal
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported